Biocogniv

Biocogniv vs Prenosis - Prenosis has a public FDA De Novo marketing authorization for Sepsis ImmunoScore. That is a regulatory milestone distinct from FDA Breakthrough Device Designation. - Biocogniv’s primary public regulatory signal is Breakthrough Device Designation for Sepsis aiMarker (vendor announcement), along with ISO 13485 certification maintenance. - Buyers who prioritize an existing FDA marketing authorization may favor solutions with De Novo or other clearance/authorization pathways; buyers focused on a laboratory-only input approach and specific integration/workflow capabilities may consider Biocogniv but should require strong local validation and references. Biocogniv vs Epic Sepsis Model - Epic’s sepsis model can be attractive to Epic customers due to in-EHR availability and potentially lower integration overhead. - EHR-native predictive alerts have been criticized in some settings for alert burden and workflow disruption (general market observation, not Biocogniv-specific). - A standalone vendor may provide more focused domain expertise and monitoring, at the cost of additional vendor management and integration work. Source illustrating presence of Epic sepsis model in educational material: - Professional society educational material and conference presentation